Corbus Pharmaceuticals Holdings, Inc.

NasdaqCM:CRBP Stock Report

Market Cap: US$169.9m

Corbus Pharmaceuticals Holdings Management

Management criteria checks 2/4

Corbus Pharmaceuticals Holdings' CEO is Yuval Cohen, appointed in Apr 2014, has a tenure of 12.25 years. total yearly compensation is $3.75M, comprised of 17.2% salary and 82.8% bonuses, including company stock and options. directly owns 0.2% of the company’s shares, worth $332.56K. The average tenure of the management team and the board of directors is 1.5 years and 3.8 years respectively.

Key information

Yuval Cohen

Chief executive officer

US$3.8m

Total compensation

CEO salary percentage17.24%
CEO tenure12.3yrs
CEO ownership0.2%
Management average tenure1.5yrs
Board average tenure3.8yrs

Recent management updates

Recent updates

Analysis Article • May 20

We're Keeping An Eye On Corbus Pharmaceuticals Holdings' (NASDAQ:CRBP) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Feb 06

Corbus Pharmaceuticals: Maintaining 'Hold' As Summer 2026 Obesity Data Catalyst Looms

Summary Corbus Pharmaceuticals maintains a 'Hold' rating as it advances CRB-701 for HNSCC and CRB-913 for obesity. CRBP expects to initiate a registrational CRB-701 study in mid-2026 and release 12-week CRB-913 obesity data in summer 2026. Early CRB-913 data show a 2.9% placebo-adjusted mean weight loss at Day 14 with a favorable safety profile and no nausea or vomiting. With $177.8M in cash post-raise, CRBP is funded into 2028, mitigating near-term dilution risk. Read the full article on Seeking Alpha
Analysis Article • Jul 07

Is Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Mar 22

Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analysis Article • Dec 06

Companies Like Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, Corbus...
Seeking Alpha • Nov 11

Corbus Pharmaceuticals' Sell-Off: Speculative Entry Price In Oncology And Obesity Therapies

Summary Corbus Pharmaceuticals still shows promise, with CRB-701 and CRB-601 advancing in clinical trials and CRB-913 targeting obesity with potentially fewer CNS side effects. Despite early-stage pipeline risks, CRBP's recent sell-off offers a favorable entry point for speculative investors, upgrading my rating from "Hold" to "Speculative Buy." CRBP's valuation is compelling with $159.4 million in liquidity and no significant debt, providing a healthy cash runway. Market concerns over CNS side effects from similar drugs may be overblown. CRB-913's design aims to avoid these issues, enhancing its blockbuster potential. CRB-913, a CB1 inverse agonist for obesity, aims to reduce CNS side effects and presents potential for combination therapy with GLP-1 agonists. Read the full article on Seeking Alpha
Seeking Alpha • Jan 30

Corbus: Ability To Have Best-In-Class Nectin-4 Targeting Drug

Summary Positive results released from phase 1 China study, using CRB-701 for the treatment of patients with metastatic urothelial carcinoma and other nectin-4 positive solid tumors. Trial initiation of phase 1 study, using CRB-701 for the treatment of patients with metastatic urothelial carcinoma and other nectin-4 positive tumors, expected in Q1 of 2024. Additional results from the phase 1 China study, using CRB-701 for the treatment of patients with nectin-4 positive solid tumors, expected at medical meetings throughout 2024. Another ADC, known as PADCEV, is expected to generate $5 billion in projected revenues in urothelial carcinoma. Read the full article on Seeking Alpha
Seeking Alpha • Aug 09

Corbus Pharmaceuticals GAAP EPS of -$0.11

Corbus Pharmaceuticals press release (NASDAQ:CRBP): Q2 GAAP EPS of -$0.11. As of June 30, 2022, the Company has $74 million of cash and investments on hand which is expected to fund operations into the first quarter of 2024, based on the current planned expenditures.

CEO Compensation Analysis

How has Yuval Cohen's remuneration changed compared to Corbus Pharmaceuticals Holdings's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$85m

Dec 31 2025US$4mUS$647k

-US$79m

Sep 30 2025n/an/a

-US$68m

Jun 30 2025n/an/a

-US$58m

Mar 31 2025n/an/a

-US$50m

Dec 31 2024US$4mUS$622k

-US$40m

Sep 30 2024n/an/a

-US$39m

Jun 30 2024n/an/a

-US$35m

Mar 31 2024n/an/a

-US$34m

Dec 31 2023US$1mUS$599k

-US$45m

Sep 30 2023n/an/a

-US$47m

Jun 30 2023n/an/a

-US$46m

Mar 31 2023n/an/a

-US$51m

Dec 31 2022US$1mUS$598k

-US$42m

Sep 30 2022n/an/a

-US$42m

Jun 30 2022n/an/a

-US$35m

Mar 31 2022n/an/a

-US$39m

Dec 31 2021US$5mUS$579k

-US$46m

Sep 30 2021n/an/a

-US$44m

Jun 30 2021n/an/a

-US$77m

Mar 31 2021n/an/a

-US$98m

Dec 31 2020US$3mUS$559k

-US$111m

Sep 30 2020n/an/a

-US$129m

Jun 30 2020n/an/a

-US$115m

Mar 31 2020n/an/a

-US$75m

Dec 31 2019US$4mUS$559k

-US$71m

Compensation vs Market: Yuval's total compensation ($USD3.75M) is above average for companies of similar size in the US market ($USD1.66M).

Compensation vs Earnings: Yuval's compensation has been consistent with company performance over the past year.

CEO

Yuval Cohen (51 yo)

12.3yrs
Tenure
US$3,750,125
Compensation

Dr. Yuval Cohen, Ph.D. has been the Chief Executive Officer and Director at Corbus Pharmaceuticals Holdings, Inc. since April 11, 2014. Dr. Cohen served as Senior Vice President at Celsus Therapeutics Plc...

Leadership Team

NamePositionTenureCompensationOwnership
Yuval Cohen
CEO & Director12.3yrsUS$3.75m0.20%
$ 332.6k
Sean Moran
Chief Financial Officer12.3yrsUS$1.79m0.15%
$ 255.8k
Ian Hodgson
Chief Operating Officer1.3yrsno data0.025%
$ 43.3k
G. Goeken
General Counsel & Corporate Secretary1.5yrsno datano data
Christina Bertsch
Vice President of Human Resources4.9yrsno datano data
Nishant Saxena
Chief Business Officerless than a yearno data0.092%
$ 155.9k
Leonardo Nicacio
Chief Medical Officerno datano datano data
1.5yrs
Average Tenure
52yo
Average Age

Experienced Management: CRBP's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Yuval Cohen
CEO & Director12.3yrsUS$3.75m0.20%
$ 332.6k
Winston Kung
Independent Director1.9yrsUS$203.20k0.045%
$ 76.5k
Brent Pfeiffenberger
Directorless than a yearno datano data
Anne Altmeyer
Independent Director3.8yrsUS$193.85k0.020%
$ 34.7k
John Jenkins
Independent Director8.1yrsUS$208.20k0.00018%
$ 305.8
Yong Ben
Independent Director3.3yrsUS$195.70k0.015%
$ 25.5k
Rachelle Jacques
Independent Chairman of the Board7.3yrsUS$215.78k0.015%
$ 25.5k
Stephen Nishimura
Member of Scientific Advisory Boardno datano datano data
3.8yrs
Average Tenure
52yo
Average Age

Experienced Board: CRBP's board of directors are considered experienced (3.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/27 03:24
End of Day Share Price 2026/07/27 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Corbus Pharmaceuticals Holdings, Inc. is covered by 22 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kalpit PatelB. Riley Securities, Inc.
Mayank MamtaniB. Riley Securities, Inc.
George ZavoicoB. Riley Securities, Inc.